1. Scrip
  2. >>Business

Is Moderna Finally Ready To Make A ‘Big Commitment’ On Not-For-Profit COVID-19 Vaccines?

Last Company To Pledge

 
• By Andrew McConaghie

Some countries want an IP waiver to boost access to vaccines, but industry leaders say this will do nothing to increase output.

Covax
The COVAX facility aims to distribute 2 billion doses in 2021, but so far has only shipped 40.5 million.

Moderna could be close to making a long-awaited pledge to supply its COVID-19 vaccine to developing world nations via a not-for-profit deal.

That is according to the company’s CEO Stephane Bancel, who has said the company’s negotiations with the COVAX facility are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By Kevin Grogan

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?